Lexicon Pharmaceuticals logo

Lexicon PharmaceuticalsNASDAQ: LXRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 April 2000

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$451.87 M
-48%vs. 3y high
64%vs. sector
-vs. 3y high
-vs. sector
-80%vs. 3y high
55%vs. sector
124.10
-97%vs. 3y high
94%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:59:29 GMT
$1.25-$0.70(-35.90%)

Dividend

No data over the past 3 years
$1.65 M$2.93 M
$1.65 M-$53.43 M

Analysts recommendations

Institutional Ownership

LXRX Latest News

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
globenewswire.com31 October 2024 Sentiment: NEGATIVE

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, as defined in the voting question as having estimated glomerular filtration rate (eGFR) > 45 to 60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g.

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
reuters.com31 October 2024 Sentiment: NEGATIVE

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
globenewswire.com16 September 2024 Sentiment: NEUTRAL

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
globenewswire.com10 September 2024 Sentiment: POSITIVE

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
zacks.com22 August 2024 Sentiment: POSITIVE

The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
zacks.com14 August 2024 Sentiment: POSITIVE

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
globenewswire.com13 August 2024 Sentiment: POSITIVE

Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
globenewswire.com07 August 2024 Sentiment: POSITIVE

THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
seekingalpha.com03 August 2024 Sentiment: NEUTRAL

Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present.

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
seekingalpha.com01 August 2024 Sentiment: NEUTRAL

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head-Investor Relations and Corporate Strategy Mike Exton – Chief Executive Officer and Director Jeff Wade – President and Chief Financial Officer Tom Garner – Senior Vice President and Chief Commercial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Alan Main – Executive Vice President, Innovation and Chemical Sciences Conference Call Participants Yasmeen Rahimi – Piper Sandler Andrew Tsai – Jefferies Joe Pantginis – H.C. Wainwright Roanna Ruiz – Leerink Partners Operator Good day and welcome to Lexicon Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.

  • 1(current)
  • 2

What type of business is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

What sector is Lexicon Pharmaceuticals in?

Lexicon Pharmaceuticals is in the Healthcare sector

What industry is Lexicon Pharmaceuticals in?

Lexicon Pharmaceuticals is in the Biotechnology industry

What country is Lexicon Pharmaceuticals from?

Lexicon Pharmaceuticals is headquartered in United States

When did Lexicon Pharmaceuticals go public?

Lexicon Pharmaceuticals initial public offering (IPO) was on 07 April 2000

What is Lexicon Pharmaceuticals website?

https://www.lexpharma.com

Is Lexicon Pharmaceuticals in the S&P 500?

No, Lexicon Pharmaceuticals is not included in the S&P 500 index

Is Lexicon Pharmaceuticals in the NASDAQ 100?

No, Lexicon Pharmaceuticals is not included in the NASDAQ 100 index

Is Lexicon Pharmaceuticals in the Dow Jones?

No, Lexicon Pharmaceuticals is not included in the Dow Jones index

When was Lexicon Pharmaceuticals the previous earnings report?

No data

When does Lexicon Pharmaceuticals earnings report?

The next expected earnings date for Lexicon Pharmaceuticals is 08 November 2024